Search

Your search keyword '"Segelmark, Mårten"' showing total 408 results
Start Over Author "Segelmark, Mårten" Language english
408 results on '"Segelmark, Mårten"'

4. The effects of plasma exchange and glucocorticoids on early kidney function among patients with ANCA-associated vasculitis in the PEXIVAS trial

Author

Paizis, Kathy, Walters, Giles, Jardine, Meg, Milton, Caroline, Ibraham, Abu, Siva, Brian, Desmond, Michael, Perkovic, Vlado, Kurtkoti, Jadadeesh, Vilayur, Eswari, Cass, Alan, Summers, Shaun, Brown, Fiona, Ryan, Jessica, Kerr, Peter, Noble, Euan, Luxton, Grant, Mudge, David W., Hawley, Carmel, Johnson, David W., Peh, Chen Au, Faull, Randall J., Ranganathan, Dwarakanathan, Jeffs, Lisa, Nicholls, Kathy, Hughes, Peter, Cooper, Bruce, Boudville, Neil, Ford, Sharon, Langham, Robyn, Reidlinger, Donna, AliciaMorrish, Badve, Sunil V., Pascoe, Elaine, Paul-Brent, Peta-Anne, Robison, Laura, Valks, Andrea, Blockmans, Daniel, Henckaerts, Liesbet, Sprangers, Ben, Suri, Rita, Brachemi, Soumeya, Clark, William, Garg, Amit, Carette, Simon, Pagnoux, Christian, Reich, Heather, Barth, David, Walsh, Michael, Khalidi, Nader, Cox, Gerry, Mazzetti, Andrea, Robins, Diane, Wald, Ron, Perl, Jeffrey, Pavenski, Katerina, Dacouris, Niki, Levin, Adeera, Copland, Michael, Fairhead, Todd, Pannu, Neesh, Qarni, Muhammad Uwais, Habib, Syed, Girard, Louis, Manns, Braden, Tesar, Vladimir, Hruskova, Zdenka, Chocova, Zdenka, Povlsen, Johan, Gregersen, Jon, Ivarsen, Per, Birn, Henrik, Krarup, Elizabeth, Pedersen, Erling B., Thomsen, Ingrid, Bech, Jesper Nørgaard, Szpirt, Wladmir, Egfjord, Martin, Mesbah, Rafik, Bataille, Pierre, Rey, Isabelle, Chantrel, François, Vanhille, Philipe, Quémeneur, Thomas, Carron, Pierre-Louis, Zaoui, Philippe, de Moreuil, Claire, Gosselin, Morgane, Delluc, Aurélien, Hanrotel-Saliou, Catherine, Le Jeune, Mathilde, Ficheux, Maxence, Aniort, Julien, Lavigne, Christian, Augusto, Jean Francois, Chauveau, Dominique, Guitard, Joëlle, Huart, Antoine, Ribes, David, Gatault, Philippe, Becmeur, Camille, Muller, Sandrine, Betz, Valérie, Klein, Alexandre, Blaison, Gilles, Seror, Raphaele, Francois, Hélène, Mariette, Xavier, Aubrun, Aurore, Coustet, Baptiste, Palazzo, Elisabeth, Ottaviani, Sébastien, Goulenok, Tiphaine, Daugas, Eric, Dieudé, Philipe, Papo, Thomas, Lebas, Céline, Lionet, Arnaud, Guillevin, Loïc, Mouthon, Luc, Puéchal, Xavier, Jourde-Chiche, Noémie, Ruivard, Marc, Karras, Alexandre, Limal, Nicolas, Kofman, Thomas, Le Quellec, Alain, Maurier, François, Gibelin, Aude, Parrot, Antoine, Bachmeyer, Claude, Gombert, Bruno, Nouvier, Mathilde, Lega, Jean-Christophe, Fain, Olivier, Andrès, Emmanuel, Cottet, Rachel, Gregorini, Gina, Jeannin, Guido, Possenti, Stefano, Buzio, Carlo, Vaglio, Augusto, Oliva, Elena, Makino, Hirofumi, Muso, Eri, Endo, Tomomi, Kakita, Hiroko, Suzuki, Hiroyuki, Handa, Takaya, Kang, Youngna, Ariyasu, Yuki, Tsukamoto, Tatsuo, Endo, Shuichiro, Miyata, Hitomi, Yamada, Hiroyuki, Ito-Ihara, Toshiko, Uchida, Shunya, Kono, Hajime, Fujigaki, Yoshihide, Kikuchi, Hirotoshi, Nanki, Toshihiro, Kato, Hideki, Okamoto, Akiko, Asako, Kurumi, Suzuki, Kazuo, Hamano, Yoshitomo, Yamagata, Kunihiro, Usui, Joichi, Fujimoto, Shouichi, Sato, Yuji, Kikuchi, Masao, Flores-Suárez, Luis Felipe, Sánchez-Guerrero, Sergio A., Collins, Michael, Schollum, John, de Zoysa, Janak, Quincy, Vicki, Sizeland, Peter, Aasarod, Knut, Solbu, Marit, Bruun, Trude Jannecke, Koldingsnes, Wenche, Wludarczyk, Anna, Nowak, Ilona, Gorka, Jacek, Sznajd, Jan, Padjas, Agnieszka, Jankowski, Milosz, Widawska, Agnieszka, Szczeklik, Wojciech, Ballarin, Jose, Bruchfeld, Annette, Efvergren, Mats, Eriksson, Per, Westman, Kerstin, Selga, Daina, Heijl, Caroline, Ohlsson, Sophie, Segelmark, Marten, Basu, Neil, Kidder, Dana, Fluck, Nicholas, Jayne, David R.W., Smith, Rona, Wilcocks, Lisa, McClure, Mark, Jones, Rachel, Trivedi, Sapna, Gopaluni, Seerapani, Brettell, Elizabeth, Crump, Paul, Feilbach, Annika, Hewitt, Catherine, Hilken, Nick, Howman, Andrew, Hughes, Terry, Ives, Natalie, Jarrett, Hugh, Mehta, Samir, Record, Rebecca, Ryan, Gemma, Sidile, Chaka, Wheatley, Keith, Sheerin, Brown, Alison, Baines, Laura Anne, Lordan, Jim, Pusey, Charles, Tanna, Anisha, McAdoo, Stephen, Levy, Jeremy, Griffith, Megan, Klebe, Bernhard, Doulton, Timothy, Warwick, Graham, Burton, James, Barratt, Jonathon, Topham, Peter, Baines, Richard, Brunskill, Nigel, Al-Jayyousi, Reem, Hamilton, Patrick, Patel, Mumtaz, Mitra, Sandip, Brown, Nina, Sharples, Edward, Luqmani, Raashid, Harper, Lorraine, Rhodes, Benjamin, Chanouzas, Dimitrios, Morgan, Matthew, Hewins, Peter, Floßmann, Oliver, Bhandary, Nitin, Foxton, Julie, Jones, Linda, King, Jenny, Smyth, Lucy, D’Souza, Richard, Haigh, Richard, Hough, Maxine, Salama, Alan, Burns, Aine, Little, Mark, Dhaun, Neeraj, Dhaygude, Ajay, Basnayake, Kolitha, Iggo, Neil, Jones, Daniel, Oliveira, David, MacPhee, Iain A.M., Dunn, Emma, Lewington, Andrew J.P., Fan, Stanley Linsun, Rajakariar, Ravindra, Yaqoob, Magdi, Short, Andrew, Geddes, Colin, Mackinnon, Bruce, Jardine, Alan G., Monach, Paul, Merkel, Peter A., Amudala, Naomi, Quillen, Karen, Weisman, Michael, Wallace, Daniel, Forbess, Lindsy, Venuturupalli, Swamy, Langford, Carol, Hajj-Ali, Rula, Koo, Anna, Hoffman, Gary, Specks, Ulrich, Keogh, Karina, Ytterberg, Steven, Winters, Jeff, Warrington, Kenneth, Cartin-Ceba, Rodrigo, Peikert, Tobias, Fervenza, Fernando, Baqir, Misbah, Nachman, Patrick, Detwiler, Randy, Mottl, Amy, Derebail, Vimal, McGregor, JulieAnne, Sreih, Antoine, Rhee, Rennie, McAlear, Carol, Aqui, Nicole, Moreland, Larry, Kiss, Joseph, Liang, Kimberly, Mohan, Niveditha, Balogun, Rasheed, Li, Tingting, Brasington, Richard, Odler, Balazs, Riedl, Regina, Geetha, Duvuru, Szpirt, Wladimir M., Uchida, Lisa, Wallace, Zachary S., Pusey, Charles D., Little, Mark A., and Kronbichler, Andreas

Published
2025
Full Text
View/download PDF

5. Data-driven subclassification of ANCA-associated vasculitis: model-based clustering of a federated international cohort

Author

Tassoni, Adrian, Mohammad, Aladdin J, Bettiol, Alessandra, Tais, Arlette, White, Arthur, Vaglio, Augusto, Terrier, Benjamin, Yaman, Beyza, Armstrong, Cecil, O'Sullivan, Declan, Wandrei, Dagmar, Kalra, Dipak, Schubach, Fabian, Dradin, François, Emmi, Giacomo, Bagni, Giacomo, Ihorst, Gabriele, Aerts, Hannelore, Kardaoui, Hicham, Mattioli, Irene, Sengers, Iris, Musial, Jacek, Scott, Jennifer, Mills, John, Julie Power, Julie, Gisslander, Karl, Wawrzycka-Adamczyk, Katarzyna, McGlinn, Kris, Wójcik, Krzysztof, Aslett, Louis, Hederman, Lucy, Dunne, Margaret, Alba, Marco A, Christofidou, Maria, Little, Mark A, Segelmark, Mårten, Crnogorac, Matija, Rutherford, Matthew, Tesi, Michelangelo, Lea, Nathan, Basu, Neil, Lamprecht, Peter, Verhoeven, Peter, de Boer, Raïssa, Straka, Richard, Lichołai, Sabina, Arnold, Sabrina, Tesar, Vladimir, Puéchal, Xavier, Hruskova, Zdenka, Hrušková, Zdenka, Musiał, Jacek, Nazeer, Jamsheela, Ng, James, and Tesař, Vladimir

Published
2024
Full Text
View/download PDF

9. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial

Author

Au Peh, Chen, Chakera, Aron, Cooper, Bruce, Kurtkoti, Jagadeesh, Langguth, Daman, Levidiotis, Vicki, Luxton, Grant, Mount, Peter, Mudge, David, Noble, Euan, Phoon, Richard, Ranganathan, Dwarakanathan, Ritchie, Angus, Ryan, Jessica, Suranyi, Michael, Rosenkranz, Alexander, Lhotta, Karl, Kronbichler, Andreas, Demoulin, Nathalie, Bovy, Christophe, Hellemans, Rachel, Hougardy, Jean-Michel, Sprangers, Ben, Wissing, Karl Martin, Pagnoux, Christian, Barbour, Sean, Brachemi, Soumeya, Cournoyer, Serge, Girard, Louis-Philippe, Laurin, Louis-Philippe, Liang, Patrick, Philibert, David, Walsh, Michael, Tesar, Vladimir, Becvar, Radim, Horak, Pavel, Rychlik, Ivan, Szpirt, Wladimir, Dieperink, Hans, Gregersen, Jon Waarst, Ivarsen, Per, Krarup, Elizabeth, Lyngsoe, Cecilie, Rigothier, Claire, Augusto, Jean-Francois, Belot, Alexandre, Chauveau, Dominique, Cornec, Divi, Jourde-Chiche, Noemie, Ficheux, Maxence, Karras, Alexandre, Klein, Alexandre, Maurier, Francois, Mesbah, Rafik, Moranne, Olivier, Neel, Antoine, Quemeneur, Thomas, Saadoun, David, Terrier, Benjamin, Zaoui, Philippe, Schaier, Matthias, Benck, Urs Tobias, Bergner, Raoul, Busch, Martin, Floege, Juergen, Grundmann, Franziska, Haller, Hermann, Haubitz, Marion, Hellmich, Bernhard, Henes, Joerg Christoph, Hohenstein, Bernd, Hugo, Christian, Iking-Konert, Christof, Arndt, Fabian, Kubacki, T, Kotter, Ina, Lamprecht, Peter, Lindner, Tom, Halbritter, Jan, Mehling, Heidrun, Schönermarck, Ulf, Venhoff, Nils, Vielhauer, Volker, Witzke, Oliver, Szombati, Istvan, Szucs, Gabriella, Garibotto, Giacomo, Alberici, Federico, Brunetta, Enrico, Dagna, Lorenzo, De Vita, Salvatore, Emmi, Giacomo, Gabrielli, Armando, Manenti, Lucio, Pieruzzi, Federico, Roccatello, Dario, Salvarani, Carlo, Harigai, Masayoshi, Dobashi, Hiroaki, Atsumi, Tatsuya, Fujimoto, Shoichi, Hagino, Noboru, Ihata, Atsushi, Kaname, Shinya, Kaneko, Yuko, Katagiri, Akira, Katayama, Masao, Kirino, Yohei, Kitagawa, Kiyoki, Komatsuda, Atsushi, Kono, Hajime, Kurasawa, Takahiko, Matsumura, Ryutaro, Mimura, Toshihide, Morinobu, Akio, Murakawa, Yohko, Naniwa, Taio, Nanki, Toshihiro, Ogawa, Noriyoshi, Oshima, Hisaji, Sada, Kenei, Sugiyama, Eiji, Takeuchi, Tohru, Taki, Hirofumi, Tamura, Naoto, Tsukamoto, Tatsuo, Yamagata, Kunihiro, Yamamura, Masahiro, van Daele, Paulus Leon Arthur, Rutgers, Abraham, Teng, Y.K. Onno, Walker, Robert, Chua, Ignatius, Collins, Michael, Rabindranath, Kannaiyan, de Zoysa, Janak, Svensson, My Hanna Sofia, Grevbo, Bard-Waldum, Kalstad, Synove, Little, Mark, Clarkson, Michael, Molloy, Eamonn, Agraz Pamplona, Irene, Anton, Jordi, Barrio Lucia, Vicente, Ciggaran, Secundino, Cinta Cid, Maria, Diaz Encarnacion, Montserrat, Fulladosa Oliveras, Xavier, Jose Soler, Maria, Marco Rusinol, Helena, Praga, Manuel, Quintana Porras, Luis, Segarra, Alfons, Bruchfeld, Annette, Segelmark, Marten, Soveri, Inga, Thomaidi, Eleni, Westman, Kerstin, Neumann, Thomas, Burnier, Michel, Daikeler, Thomas, Dudler, Jean, Hauser, Thomas, Seeger, Harald, Vogt, Bruno, Burton, James, Al Jayyousi, Reem, Amin, Tania, Andrews, Jacqueline, Baines, Laura Anne, Brogan, Paul, Dasgupta, Bhaskar, Doulton, Timothy William Ronald, Flossmann, Oliver, Griffin, Sian V., Harper, Janice Marian, Harper, Lorraine, Kidder, Dana, Klocke, Rainer, Lanyon, Peter Charles, Luqmani, Raashid, McLaren, John Stuart, Makanjuola, David Osagie, McCann, Liza, Nandagudi, Anupama C., Selvan, Shilpa, O'Riordan, Edmond, Patel, Mumtaz, Patel, Rajan Kantilal, Pusey, Charles Dickson, Rajakariar, Ravindra, Robson, Joanna C., Robson, Michael, Salama, Alan David, Smyth, Lucy, Sznajd, Jan, Taylor, Joanne, Sreih, Antonie G., Belilos, Elise, Bomback, Andrew S., Carlin, Jeffrey, Chang Chen Lin, Yih, Derebail, Vimal K., Dragoi, Serban, Dua, Anisha, Forbess, Lindsy, Geetha, Duvuru, Gipson, Patrick, Gohh, Reginald, Greenwood, Gregory Todd, Hugenberg, Steven T., Jimenez, Richard A.H., Kaskas, Marwan Omar, Kermani, Tanaz, Kivitz, Alan J., Koening, Curry, Langford, Carol A., Marder, Galina, Mohamed, Amr Ahmed El-Huesseini, Monach, Paul, Neyra, Nilda Roxana, Niemer, Gregory W., Niles, John, Obi, Reginald, Owens, Charles, Parks, Deborah L., Podoll, Amber S., Rovin, Brad, Sam, R, Shergy, William Julius, Silva, Arnold Lawrence, Specks, Ulrich, Spiera, Robert, Springer, Jason M., Striebich, Christopher Charles, Swarup, Areena, Thakar, Surabhi, Tiliakos, Athan N., Tsai, Yong, Waguespack, Dia R., Chester Wasko, Mary, Strand, Vibeke, Jayne, David R W, Horomanski, Audra, Yue, Huibin, Bekker, Pirow, and Merkel, Peter A

Published
2023
Full Text
View/download PDF

10. IgA vasculitis nephritis—outcomes in adult-onset disease.

Author

Stanway, James, Brown, Nina, Pervez, Afeera, Perre, Els Van de, Tollitt, James, Marketos, Nikolaos, Wong, Nikki, Dhaygude, Ajay, Ponnusamy, Arvind, O'Riordan, Ed, Venning, Michael, Segelmark, Mårten, Morgan, Matthew, Jayne, David, Hamilton, Patrick, Pusey, Charles D, Oni, Louise, and Salama, Alan D

Abstract

Objectives IgA vasculitis (IgAV) in adults has been relatively under-investigated. Since outcomes are worse in other forms of vasculitis with increasing age, we investigated the outcomes of IgAV comparing younger adults (18–34), middle-aged adults (35–64) and elderly patients (≥64 years) focusing on kidney outcomes. Methods We identified patients with renal biopsy-confirmed IgAV nephritis and collected data regarding clinical features and progression to end stage kidney disease (ESKD). The relationship between patient factors and ESKD was analysed by regression. Results We identified 202 cases, 34% aged 18–34, 43% aged 35–64 and 23% elderly (>64 years). Median follow-up was 44 months. Elderly patients were more likely to present with ESKD (23.9%) compared with middle-aged (13.7%) and younger adults (2.9%) (χ2 11.6, P  = 0.002). In patients with independent kidney function at biopsy, there was no difference in outcomes between age groups. Male gender, Black ethnicity, diabetes, histological evidence of chronic renal damage and estimated glomerular filtration rate < 30 ml/min were risk factors for development of ESKD. In this observational study 68.3% of patients received glucocorticoids and 56.9% additional immunosuppression. Conclusion Elderly patients with IgAV are more likely to have ESKD at presentation, but there is no difference in renal survival between age groups, among those presenting with independent renal function. Renal impairment at biopsy is an independent risk factor for subsequent development of ESKD. There is significant variability in the timing of kidney biopsy and management of these patients among specialist centres. Young adults have outcomes more in keeping with childhood IgAV. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

11. Primary glomerular diseases and long‐term adverse health outcomes: A nationwide cohort study.

Author

Faucon, Anne‐Laure, Lando, Stefania, Chrysostomou, Charikleia, Wijkström, Julia, Lundberg, Sigrid, Bellocco, Rino, Segelmark, Mårten, Evans, Marie, and Carrero, Juan‐Jesús

Subjects
KIDNEY glomerulus diseases, DIABETIC nephropathies, FOCAL segmental glomerulosclerosis, RENAL replacement therapy, IGA glomerulonephritis
Abstract

Background: Although glomerular diseases are the third most frequent cause of end‐stage kidney disease worldwide, little is known about their long‐term outcomes. Methods: In patients with chronic kidney disease (CKD) stage 3–5 enrolled in the Swedish Renal Registry, we compared risks of hospitalization, kidney replacement therapy (KRT), major cardiovascular events (MACE), and death of the four most frequent primary glomerular diseases (IgA nephropathy [IgAN], focal segmental glomerulosclerosis [FSGS], minimal change disease [MCD], and membranous nephropathy [MN]), and patients with CKD due to the most common non‐communicable diseases (control‐CKD). Results: We identified 2396 patients with glomerular disease (97% biopsy‐proven, 69% men, 57 years, eGFR 29 mL/min/1.73 m2, uACR 88 mg/mmol, 1524 with IgAN, 398 FSGS, 94 MCD, and 380 MN) and 37,697 controls (64% men, 74 years, eGFR 25 mL/min/1.73 m2, uACR 23 mg/mmol), mainly with diabetic nephropathy and nephroangiosclerosis. The median follow‐up was 6.3 (3.3; 9.9) years. Compared with control‐CKD, patients with primary glomerular diseases generally had a lower risk of hospitalization, MACE (adjusted hazard ratios [HRs] ranging from 0.44 to 0.88 depending on the etiology) and death (HRs ranging 0.45–0.76). Patients with IgAN and FSGS had a faster eGFR decline and a higher rate of KRT (HRs 1.26 [95%CI: 1.15–1.37] and 1.34 [1.15–1.57], respectively). Conversely, patients with MN and MCD had a lower KRT rate and slower eGFR decline. Conclusion: Despite having a lower relative risk of hospitalization, cardiovascular events and mortality, patients with IgAN and FSGS are at higher risk of CKD progression than the most common etiologies of CKD, emphasizing the need for more stringent treatment strategies in these patients. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

12. Time trends in preemptive kidney transplantation in Europe: an ERA registry study.

Author

Kramer, Anneke, Boenink, Rianne, Vergara, Cynthia G Mercado, Bell, Samira, Kerschbaum, Julia, Arévalo, Olga L Rodríguez, Mazuecos, Auxiliadora, Vries, Aiko P J de, Reisæter, Anna V, Wong, Esther H S, Lundgren, Torbjörn, Valentin, María O, Alvarez, Flor A Ordoñez, Melilli, Edoardo, Finne, Patrik, Segelmark, Mårten, Couchoud, Cécile, Sørensen, Søren S, Ferraro, Pietro Manuel, and Arnol, Miha

Subjects
KIDNEY transplantation, CONSCIOUSNESS raising, KIDNEY diseases, ADULTS, KIDNEYS
Abstract

Background Preemptive kidney transplantation (PEKT) has better outcomes when compared with transplantation after dialysis. We aimed to examine trends in PEKT between 2000 and 2019 in Europe and to provide an overview of associated policies, barriers and initiatives. Methods Adult patients from 12 European countries who received a preemptive kidney transplant were included. The representatives of the registries providing these data were questioned on the policies, barriers and initiatives around PEKT. Results Between 2000 and 2019, 20 251 adults underwent PEKT [11 169 from living donors (LDs), 8937 from deceased donors (DDs)]. The proportion of first kidney transplantations that were preemptive more than doubled from 7% in 2000 to 18% in 2019, reflecting a similar relative increase for LD kidney recipients (from 21% to 43%) and DD kidney recipients (from 4% to 11%). Large international differences were found. The increase in PEKT was observed across all age, sex and primary renal disease groups. Countries had similar criteria for preemptive waitlisting. Barriers mentioned included donor shortage, late referral to the transplant center and long donor or recipient work-up. Suggested initiatives included raising awareness on the possibility of PEKT, earlier start and shorter work-up time for recipient and LD. Conclusions Over the last two decades the proportion of patients receiving a first kidney transplant preemptively has more than doubled, reflecting a similar relative increase for living and DD kidney recipients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Incidence of Kidney Replacement Therapy and Subsequent Outcomes Among Patients With Systemic Lupus Erythematosus: Findings From the ERA Registry

Author

Derner, Ondrej, Kramer, Anneke, Hruskova, Zdenka, Arici, Mustafa, Collart, Frederic, Finne, Patrik, Fuentes Sánchez, Laura, Harambat, Jérôme, Hemmelder, Marc H., Hommel, Kristine, Kerschbaum, Julia, De Meester, Johan, Palsson, Runolfur, Segelmark, Mårten, Skrunes, Rannveig, Traynor, Jamie P., Zurriaga, Oscar, Massy, Ziad A., Jager, Kitty J., Stel, Vianda S., and Tesar, Vladimir

Published
2022
Full Text
View/download PDF

15. Rituximab in Membranous Nephropathy

Author

Gauckler, Philipp, Shin, Jae Il, Alberici, Federico, Audard, Vincent, Bruchfeld, Annette, Busch, Martin, Cheung, Chee Kay, Crnogorac, Matija, Delbarba, Elisa, Eller, Kathrin, Faguer, Stanislas, Galesic, Kresimir, Griffin, Siân, van den Hoogen, Martijn W.F., Hrušková, Zdenka, Jeyabalan, Anushya, Karras, Alexandre, King, Catherine, Kohli, Harbir Singh, Mayer, Gert, Maas, Rutger, Muto, Masahiro, Moiseev, Sergey, Odler, Balazs, Pepper, Ruth J., Quintana, Luis F., Radhakrishnan, Jai, Ramachandran, Raja, Salama, Alan D., Schönermarck, Ulf, Segelmark, Mårten, Smith, Lee, Tesař, Vladimír, Wetzels, Jack, Willcocks, Lisa, Windpessl, Martin, Zand, Ladan, Zonozi, Reza, and Kronbichler, Andreas

Published
2021
Full Text
View/download PDF

16. Collagen IVα345 dysfunction in glomerular basement membrane diseases. I. Discovery of a COL4A3 variant in familial Goodpasture’s and Alport diseases

Author

Pokidysheva, Elena N., Seeger, Harald, Pedchenko, Vadim, Chetyrkin, Sergei, Bergmann, Carsten, Abrahamson, Dale, Cui, Zhao Wei, Delpire, Eric, Fervenza, Fernando C., Fidler, Aaron L., Fogo, Agnes B., Gaspert, Ariana, Grohmann, Maik, Gross, Oliver, Haddad, George, Harris, Raymond C., Kashtan, Clifford, Kitching, A. Richard, Lorenzen, Johan M., McAdoo, Stephen, Pusey, Charles D., Segelmark, Marten, Simmons, Alicia, Voziyan, Paul A., Wagner, Timo, Wüthrich, Rudolf P., Zhao, Ming-Hui, Boudko, Sergei P., Kistler, Andreas D., and Hudson, Billy G.

Published
2021
Full Text
View/download PDF

17. Changes in the epidemiology of kidney replacement therapy across Europe in 2020—the first year of the COVID-19 pandemic: an ERA Registry study.

Author

Kramer, Anneke, Jager, Kitty J, Chesnaye, Nicholas C, Kerschbaum, Julia, Hommel, Kristine, Farnés, Jordi Comas, Alemán, Sara Trujillo, Santamaria, Rafael, Finne, Patrik, Hemmelder, Marc H, Åsberg, Anders, Nitsch, Dorothea, Ambühl, Patrice, Sørensen, Søren S, Sánchez-Alvarez, J Emilio, Segelmark, Mårten, Resic, Halima, Ots-Rosenberg, Mai, Radunovic, Danilo, and Palsson, Runolfur

Subjects
RENAL replacement therapy, COVID-19 pandemic, COVID-19, KIDNEY transplantation, PERITONEAL dialysis
Abstract

Background In 2020, the coronavirus disease 2019 (COVID-19) pandemic caused disruptions in kidney replacement therapy (KRT) services worldwide. The aim of this study was to assess the effect of the COVID-19 pandemic in 2020 on the incidence of KRT, kidney transplantation activity, mortality and prevalence of KRT across Europe. Methods Patients receiving KRT were included from 17 countries providing data to the European Renal Association Registry. The epidemiology of KRT in 2020 was compared with average data from the period 2017–2019. Changes occurring during the first and second waves of the pandemic were also explored. Results The incidence of KRT was 6.2% lower in 2020 compared with 2017–2019, with the lowest point (−22.7%) during the first wave in April. The decrease varied across countries, was smaller in males (−5.2%) than in females (−8.2%) and was moderate for peritoneal dialysis (−3.7%) and haemodialysis (−5.4%) but substantial for pre-emptive kidney transplantation (−23.6%). The kidney transplantation rate decreased by 22.5%, reaching a nadir of −80.1% during the first wave, and was greatest for living donor kidney transplants (−30.5%). While in most countries the kidney transplantation rate decreased, in the Nordic/Baltic countries and Greece there was no clear decrease. In dialysis patients, mortality increased by 11.4% and was highest in those 65–74 years of age (16.1%), in those with diabetes as the primary renal disease (15.1%) and in those on haemodialysis (12.4%). In transplant recipients, the mortality was 25.8% higher, but there were no subgroups that stood out. In contrast to the rising prevalence of KRT observed over the past decades across Europe, the prevalence at the end of 2020 (N  = 317 787) resembled that of 2019 (N  = 317 077). Conclusion The COVID-19 pandemic has had a substantial impact on the incidence of KRT, kidney transplant activity, mortality of KRT and prevalence of KRT in Europe with variations across countries. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?

Author

Gauckler, Philipp, Shin, Jae Il, Alberici, Federico, Audard, Vincent, Bruchfeld, Annette, Busch, Martin, Cheung, Chee Kay, Crnogorac, Matija, Delbarba, Elisa, Eller, Kathrin, Faguer, Stanislas, Galesic, Kresimir, Griffin, Siân, Hrušková, Zdenka, Jeyabalan, Anushya, Karras, Alexandre, King, Catherine, Kohli, Harbir Singh, Maas, Rutger, Mayer, Gert, Moiseev, Sergey, Muto, Masahiro, Odler, Balazs, Pepper, Ruth J., Quintana, Luis F., Radhakrishnan, Jai, Ramachandran, Raja, Salama, Alan D., Segelmark, Mårten, Tesař, Vladimír, Wetzels, Jack, Willcocks, Lisa, Windpessl, Martin, Zand, Ladan, Zonozi, Reza, and Kronbichler, Andreas

Published
2020
Full Text
View/download PDF

19. 2020 international consensus on ANCA testing beyond systemic vasculitis

Author

Moiseev, Sergey, Cohen Tervaert, Jan Willem, Arimura, Yoshihiro, Bogdanos, Dimitrios P., Csernok, Elena, Damoiseaux, Jan, Ferrante, Marc, Flores-Suárez, Luis Felipe, Fritzler, Marvin J., Invernizzi, Pietro, Jayne, David, Jennette, J. Charles, Little, Mark A., McAdoo, Stephen P., Novikov, Pavel, Pusey, Charles D., Radice, Antonella, Salama, Alan D., Savige, Judith A., Segelmark, Mårten, Shoenfeld, Yehuda, Sinico, Renato A., Sousa, Maria-José, Specks, Ulrich, Terrier, Benjamin, Tzioufas, Athanasios G., Vermeire, Severine, Zhao, Ming-Hui, and Bossuyt, Xavier

Published
2020
Full Text
View/download PDF

21. Evaluation of the ACR/EULAR 2022 criteria for classification of ANCA-associated vasculitis in a population-based cohort from Sweden.

Author

Rathmann, Jens, Segelmark, Mårten, and Mohammad, Aladdin J

Subjects
*VASCULITIS, *RESEARCH funding, *ANTINEUTROPHIL cytoplasmic antibodies, *MICROSCOPIC polyangiitis, *DESCRIPTIVE statistics, *GRANULOMATOSIS with polyangiitis, *STATISTICS, *CHURG-Strauss syndrome, *RHEUMATOLOGY, *CONFIDENCE intervals, *COMPARATIVE studies, *ALGORITHMS, *NOSOLOGY, *SENSITIVITY & specificity (Statistics), *INTER-observer reliability, *BLOOD
Abstract

Objective To evaluate the ACR/EULAR 2022 criteria for ANCA-associated vasculitides (AAV) classification and compare them with the European Medicines Agency (EMA) algorithm and with classification based only on ANCA serology. Methods In the analysis, 374 cases (47% female) were classified according to the EMA algorithm, ANCA serology and ACR/EULAR criteria. The agreement rate was calculated using the kappa (κ) statistic. Results Under EMA, 192 patients were classified as granulomatosis with polyangiitis (GPA), 159 as microscopic polyangiitis (MPA) and 23 as eosinophilic granulomatosis with polyangiitis (EGPA). The ACR/EULAR criteria classified 199 patients as GPA, 136 as MPA and 22 as EGPA. Four patients (1.1%) met criteria of two disease categories, and 13 (3.5%) were unclassifiable. The observed agreement between EMA and ACR/EULAR was 85% for GPA, 75% for MPA and 96% for EGPA. The unweighted κ statistic was 0.66 (95% CI: 0.60, 0.74). Of the 188 PR3-ANCA positive patients, 186 (98.9%) were classified as GPA using ACR/EULAR criteria, and 135 of 161 (83.9%) MPO-ANCA positive patients were classified as MPA. With a classification solely based on ANCA specificity, agreement with ACR/EULAR was 99% for GPA and 88% for MPA. Conclusions EMA and ACR/EULAR classification give similar results. A small proportion of patients cannot be classified or fall into two categories. Some patients exhibiting granuloma, a key feature of GPA, are nevertheless classified as MPA, conflicting with the current view of histopathology of AAV. There is high agreement of ANCA-based classification with that of ACR/EULAR, reflected in the considerable weight granted to ANCA in the new criteria. These crucial elements within the new criteria necessitate a consensus discussion among field experts. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies

Author

Appel, Lawrence J, Greene, Tom, Chen, Teresa K, Chalmers, John, Arima, Hisatomi, Perkovic, Vlado, Levin, Adeera, Djurdjev, Ognjenka, Tang, Mila, Nally, Joseph, Navaneethan, Sankar D, Schold, Jesse D, Weldegiorgis, Misghina, Herrington, William G, Smith, Margaret, Hsu, C Yenchih, Hwang, Shih-Jen, Chang, Alex R, Kirchner, H. Lester, Green, Jamie A, Ho, Kevin, Marks, Angharad, Prescott, Gordon, Clark, Laura E, Fluck, Nick, Shalev, Varda, Chodick, Gabriel, Blankestijn, Peter J, Van Zuilen, Arjan, Van den Brand, Jan A, Sarnak, Mark J, Bottinger, Erwin, Nadkarni, Girish N, Ellis, Stephen G, Nadukuru, Rajiv, Metzger, Marie, Flamant, Martin, Houillier, Pascal, Haymann, Jean-Philippe, Froissart, Marc, Kenealy, Timothy, Elley, Raina C, Collins, John F, Drury, Paul L, Cuddeback, John K, Ciemins, Elizabeth L, Stempniewicz, Rich, Nelson, Robert G, Knowler, William C, Bakker, Stephen J, Major, Rupert W, Medcalf, James F, Shepherd, David, Barrett-Connor, Elizabeth, Bergstrom, Jaclyn, Ix, Joachim H, Molnar, Miklos Z, Sumida, Keiichi, de Zeeuw, Dick, Brenner, Barry, Qureshi, Abdul R, Elinder, Carl-Gustaf, Runesson, Bjorn, Evans, Marie, Segelmark, Marten, Stendahl, Maria, Schön, Staffan, Naimark, David M, Tangri, Navdeep, Sud, Maneesh, Hirayama, Atsushi, Ichikawa, Kazunobu, Bilo, Henk JG, Landman, Gijs WD, Van Hateren, Kornelis JJ, Kleefstra, Nanne, Hallan, Stein I, Ballew, Shoshana H, Chen, Jingsha, Kwak, Lucia, Surapaneni, Aditya, Parving, Hans-Henrik, Rodby, Roger A., Rohde, Richard D, Lewis, Julia B, Lewis, Edmund, Perrone, Ronald D, Abebe, Kaleab Z, Hou, Fan F, Xie, Di, Hunsicker, Lawrence G, Imai, Enyu, Kobayashi, Fumiaki, Makino, Hirofumi, Ito, Sadayoshi, Remuzzi, Giuseppe, Ruggenenti, Piero, Eckardt, Kai-Uwe, Gudmundsdottir, Hrefna, Maciulaitis, Romaldas, Manley, Tom, Smith, Kimberly, Stockbridge, Norman, Thompson, Aliza, Vetter, Thorsten, Willis, Kerry, Zhang, Luxia, Coresh, Josef, Heerspink, Hiddo J L, Sang, Yingying, Matsushita, Kunihiro, Arnlov, Johan, Astor, Brad C, Black, Corri, Brunskill, Nigel J, Carrero, Juan-Jesus, Feldman, Harold I, Fox, Caroline S, Inker, Lesley A, Ishani, Areef, Jassal, Simerjot, Konta, Tsuneo, Polkinghorne, Kevan, Romundstad, Solfrid, Solbu, Marit D, Stempniewicz, Nikita, Stengel, Benedicte, Tonelli, Marcello, Umesawa, Mitsumasa, Waikar, Sushrut S, Wen, Chi-Pang, Wetzels, Jack F M, Woodward, Mark, Grams, Morgan E, Kovesdy, Csaba P, Levey, Andrew S, and Gansevoort, Ron T

Published
2019
Full Text
View/download PDF

23. Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium

Author

Astor, Brad, Appel, Larry, Greene, Tom, Chen, Teresa, Chalmers, John, Woodward, Mark, Arima, Hisatomi, Perkovic, Vlado, Yatsuya, Hiroshi, Tamakoshi, Koji, Li, Yuanying, Hirakawa, Yoshihisa, Coresh, Josef, Matsushita, Kunihiro, Grams, Morgan, Sang, Yingying, Polkinghorne, Kevan, Chadban, Steven, Atkins, Robert, Levin, Adeera, Djurdjev, Ognjenka, Zhang, Luxia, Liu, Lisheng, Zhao, Minghui, Wang, Fang, Wang, Jinwei, Schaeffner, Elke, Ebert, Natalie, Martus, Peter, Tang, Mila, Heine, Gunnar, Emrich, Insa, Seiler, Sarah, Zawada, Adam, Nally, Joseph, Navaneethan, Sankar, Schold, Jesse, Shlipak, Michael, Sarnak, Mark, Katz, Ronit, Hiramoto, Jade, Iso, Hiroyasu, Yamagishi, Kazumasa, Umesawa, Mitsumasa, Muraki, Isao, Fukagawa, Masafumi, Maruyama, Shoichi, Hamano, Takayuki, Hasegawa, Takeshi, Fujii, Naohiko, Wheeler, David, Emberson, John, Townend, John, Landray, Martin, Brenner, Hermann, Schöttker, Ben, Saum, Kai-Uwe, Rothenbacher, Dietrich, Fox, Caroline, Hwang, Shih-Jen, Köttgen, Anna, Kronenberg, Florian, Schneider, Markus P., Eckardt, Kai-Uwe, Green, Jamie, Kirchner, H Lester, Chang, Alex R., Ho, Kevin, Ito, Sadayoshi, Miyazaki, Mariko, Nakayama, Masaaki, Yamada, Gen, Cirillo, Massimo, Irie, Fujiko, Sairenchi, Toshimi, Ishikawa, Shizukiyo, Yano, Yuichiro, Kotani, Kazuhiko, Nakamura, Takeshi, Jee, Sun Ha, Kimm, Heejin, Mok, Yejin, Chodick, Gabriel, Shalev, Varda, Wetzels, Jack F.M., Blankestijn, Peter J., van Zuilen, Arjan D., van den Brand, Jan, Inker, Lesley, Peralta, Carmen, Kollerits, Barbara, Ritz, Eberhard, Nitsch, Dorothea, Roderick, Paul, Fletcher, Astrid, Bottinger, Erwin, Nadkarni, Girish N., Ellis, Stephen B., Nadukuru, Rajiv, Ueshima, Hirotsugu, Okayama, Akira, Miura, Katsuyuki, Tanaka, Sachiko, Okamura, Tomonori, Kadota, Aya, Kenealy, Timothy, Elley, C Raina, Collins, John F., Drury, Paul L., Ohkubo, Takayoshi, Asayama, Kei, Metoki, Hirohito, Kikuya, Masahiro, Nelson, Robert G., Knowler, William C., Gansevoort, Ron T., Bakker, Stephan JL., Hak, Eelco, Heerspink, Hiddo J.L., Brunskill, Nigel, Major, Rupert, Shepherd, David, Medcalf, James, Jassal, Simerjot K., Bergstrom, Jaclyn, Ix, Joachim H., Barrett-Connor, Elizabeth, Kovesdy, Csaba, Kalantar-Zadeh, Kamyar, Sumida, Keiichi, Gutierrez, Orlando M., Muntner, Paul, Warnock, David, McClellan, William, de Zeeuw, Dick, Brenner, Barry, Sedaghat, Sanaz, Ikram, M Arfan, Hoorn, Ewout J., Dehghan, Abbas, Carrero, Juan J., Gasparini, Alessandro, Wettermark, Björn, Elinder, Carl-Gustaf, Wong, Tien Yin, Sabanayagam, Charumathi, Cheng, Ching-Yu, Visseren, Frank L.J., Evans, Marie, Segelmark, Mårten, Stendahl, Maria, Schön, Staffan, Tangri, Navdeep, Sud, Maneesh, Naimark, David, Wen, Chi-Pang, Tsao, Chwen-Keng, Tsai, Min-Kugng, Chen, Chien-Hua, Konta, Tsuneo, Hirayama, Atsushi, Ichikawa, Kazunobu, Lannfelt, Lars, Larsson, Anders, Ärnlöv, Johan, Bilo, Henk J.G., Landman, Gijs W.D., van Hateren, Kornelis J.J., Kleefstra, Nanne, Coresh (Chair, Josef, Grams, Morgan E., Hallan, Stein, Kovesdy, Csaba P., Levey, Andrew S., Ballew, Shoshana H., Chen, Jingsha, Kwak, Lucia, Surapaneni, Aditya, Inker, Lesley A., Heine, Gunnar H., Landray, Martin J., Peralta, Carmen A., Shlipak, Michael G., and Hallan, Stein I.

Published
2019
Full Text
View/download PDF

24. Characteristics and Outcomes of Patients With Systemic Sclerosis (Scleroderma) Requiring Renal Replacement Therapy in Europe: Results From the ERA-EDTA Registry

Author

Hruskova, Zdenka, Pippias, Maria, Stel, Vianda S., Abad-Díez, Jose M., Benítez Sánchez, Manuel, Caskey, Fergus J., Collart, Frederic, De Meester, Johan, Finne, Patrik, Heaf, James G., Magaz, Angela, Palsson, Runolfur, Reisæter, Anna Varberg, Salama, Alan D., Segelmark, Mårten, Traynor, Jamie P., Massy, Ziad A., Jager, Kitty J., and Tesar, Vladimir

Published
2019
Full Text
View/download PDF

27. Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data

Author

Chalmers, John, Arima, Hisatomi, Perkovic, Vlado, Grams, Morgan E., Sang, Yingying, Schaeffner, Elke, Martus, Peter, Levin, Adeera, Djurdjev, Ognjenka, Tang, Mila, Heine, Gunnar, Seiler, Sarah, Zawada, Adam, Emrich, Insa, Sarnak, Mark, Katz, Ronit, Brenner, Hermann, Schöttker, Ben, Rothenbacher, Dietrich, Saum, Kai-Uwe, Köttgen, Anna, Schneider, Markus, Eckardt, Kai-Uwe, Green, Jamie, Kirchner, H Lester, Chang, Alex R, Black, Corri, Marks, Angharad, Prescott, Gordon, Clark, Laura, Fluck, Nick, Jee, Sun Ha, Mok, Yejin, Chodick, Gabriel, Shalev, Varda, Wetzels, Jack F.M., Blankestijn, Peter J, van Zuilen, Arjan D, Bots, M, Peralta, Carmen, Hiromoto, Jade, Bottinger, Erwin, Nadkarni, Girish N, Ellis, Stephen B, Nadukuru, Rajiv, Kenealy, Timothy, Elley, C Raina, Collins, John F, Drury, Paul L, Bakker, Stephan JL, Heerspink, Hiddo J Lambers, Jassal, Simerjot K, Bergstrom, Jaclyn, Ix, Joachim H, Barrett-Connor, Elizabeth, Kalantar-Zadeh, Kamyar, Carrero, Juan J, Gasparini, Alessandro, Qureshi, Abdul Rashid, Barany, Peter, Algra, Ale, van der Graaf, Yolanda, Evans, Marie, Segelmark, Mårten, Stendahl, Maria, Schön, Staffan, Tangri, Navdeep, Sud, Maneesh, Naimark, David, Lannfelt, Lars, Larsson, Anders, Hallan, Stein, Levey, Andrew S, Chen, Jingsha, Kwak, Lucia, Matsushita, Kunihiro, Ballew, Shoshana H, Coresh, Josef, Ärnlöv, Johan, Cirillo, Massimo, Ebert, Natalie, Hiramoto, Jade S, Kimm, Heejin, Shlipak, Michael G, Visseren, Frank L J, Gansevoort, Ron T, Kovesdy, Csaba P, Woodward, Mark, and Kronenberg, Florian

Published
2017
Full Text
View/download PDF

29. International comparison and time trends of first kidney transplant recipient characteristics across Europe: an ERA Registry study.

Author

Boenink, Rianne, Kramer, Anneke, Masoud, Sherry, Rodríguez-Benot, Alberto, Helve, Jaakko, Bistrup, Claus, Segelmark, Mårten M, Arévalo, Olga L Rodríguez, Kerschbaum, Julia, Vries, Aiko P J de, Lundgren, Torbjörn, Bell, Samira, Crespo, Marta, Sørensen, Søren S, Ferraro, Pietro Manuel, Arnol, Miha, Bakkaloglu, Sevcan A, Weekers, Laurent, Reisæter, Anna Varberg, and Rebić, Damir

Subjects
KIDNEY transplantation, AGE differences, AGE distribution, KIDNEY diseases, DIABETES
Abstract

Background The aim of this study was to provide an overview of age, sex and primary renal disease (PRD) distribution among first kidney transplant recipients across Europe. Method The European Renal Association (ERA) Registry database was used to obtain data on patients aged 20 years or older receiving their first kidney transplant between 2010 and 2019 from 12 European countries. The numbers and percentages of recipients in each age, sex and PRD group were calculated by country, donor type and year. Results In total, 99 543 adults received a first kidney transplant. Overall, 23% of the recipients were 65 years or older, 36% were female, and 21% had glomerulonephritis and 15% diabetes mellitus as PRD. Compared with deceased donor kidney transplant recipients, living donor kidney transplant recipients were less often 65 years or older (13% versus 26%), more often had glomerulonephritis (25% versus 20%) and less often diabetes mellitus (8% versus 17%) as PRD. We found large international differences, which were most prominent for age and PRD and less prominent for sex. Over time, the largest change in recipient characteristics was observed for the percentage of recipients aged 65 years or older, increasing from 18% in 2010 to 28% in 2019 for all countries combined with a similar trend in most countries. Conclusion We observed large differences for age and PRD distribution between recipients of living and deceased donor kidneys and between European countries. Over time, the percentage of older first kidney transplant recipients increased. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. The HLA region in ANCA-associated vasculitis: characterisation of genetic associations in a Scandinavian patient population.

Author

Lundtoft, Christian, Knight, Ann, Meadows, Jennifer R. S., Karlsson, Åsa, Rantapää-Dahlqvist, Solbritt, Berglin, Ewa, Palm, Øyvind, Haukeland, Hilde, Gunnarsson, Iva, Bruchfeld, Annette, Segelmark, Mårten, Ohlsson, Sophie, Mohammad, Aladdin J., Eriksson, Per, Söderkvist, Peter, Ronnblom, Lars, Omdal, Roald, Jonsson, Roland, Lindblad-Toh, Kerstin, and Dahlqvist, Johanna

Published
2024
Full Text
View/download PDF

32. Imlifidase in kidney transplantation.

Author

Kanbay, Mehmet, Copur, Sidar, Guldan, Mustafa, Topcu, Ahmet U, Ozbek, Lasin, Hasbal, Baris, Süsal, Caner, Kocak, Burak, Callemeyn, Jasper, and Segelmark, Mårten

Subjects
KIDNEY transplantation, GRAFT rejection, HLA histocompatibility antigens, CHRONIC kidney failure, MEDICAL protocols
Abstract

Kidney transplantation, the gold-standard therapeutic approach for patients with end-stage kidney disease, offers improvement in patient survival and quality of life. However, broad sensitization against human leukocyte antigens often resulting in a positive crossmatch against the patient's living donor or the majority of potential deceased donors in the allocation system represents a major obstacle due to a high risk for antibody-mediated rejection, delayed graft function and allograft loss. Kidney-paired donation and desensitization protocols have been established to overcome this obstacle, with limited success. Imlifidase, a novel immunoglobulin G (IgG)-degrading enzyme derived from Streptococcus pyogenes and recombinantly produced in Escherichia coli , is a promising agent for recipients with a positive crossmatch against their organ donor with high specificity towards IgG, rapid action and high efficacy in early pre-clinical and clinical studies. However, the rebound of IgG after a few days can lead to antibody-mediated rejection, making the administration of potent immunosuppressive regimens in the early post-transplant phase necessary. There is currently no comparative study evaluating the efficiency of imlifidase therapy compared with conventional desensitization protocols along with the lack of randomized control trials, indicating the clear need for future large-scale clinical studies in this field. Besides providing a practical framework for the clinical use of the agent, our aim in this article is to evaluate the underlying mechanism of action, efficiency and safety of imlifidase therapy in immunologically high-risk kidney transplant recipients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. A population-based study on the incidence and aetiology of infectious complications in peritoneal dialysis in South Sweden.

Author

Tobijaszewska, Marta, Martus, Giedre, Sunnerhagen, Torgny, Segelmark, Mårten, and Ljungquist, Oskar

Subjects
PERITONEAL dialysis, ETIOLOGY of diseases, MEDICAL microbiology, ESCHERICHIA coli, GRAM-positive bacteria, CHRONIC kidney failure, URINARY tract infections, CATHETER-related infections
Abstract

Peritonitis is a major cause of morbidity in peritoneal dialysis (PD) and an independent risk factor for elevated all-cause mortality. The aims of this study were to report the incidence, trend, aetiology, and antimicrobial susceptibility of PD-associated peritonitis and catheter-related infections in South Sweden between 2011–2020. This population-based observational cohort study included all patients with PD between the years 2011–2020 in the county of Skåne. Data was accessed through the Swedish Renal Registry and the Department of Clinical Microbiology in Lund. Definitions issued by the International Society for Peritoneal Dialysis were implemented to assess PD-associated infections. Medical records of 675 paediatric and adult PD patients were eligible for inclusion. Of those, 208 (31%) were female and the median age was 67 years (range 0-91). The overall rate of PD-peritonitis was 0.38 episodes per year at risk. Out of 484 episodes of peritonitis, 61% (n = 295) were caused by Gram-positive bacteria. There were 289 occurrences of exit site infections, of which most (n = 152, 53%) were Gram-positive. Tunnel infections occurred in 16 episodes and were caused by S. aureus or P. aeruginosa. Among all isolates, 37 were of MRSE, four of ESBL-producing E. coli, and one of MRSA. The crude rate of PD-peritonitis was stable during the study period. Gram-positive bacteria dominated the microbial aetiology, and antibiotic resistance was limited. It is important to monitor the aetiology, incidence, and resistance rates in PD-associated infections, to base empirical antibiotic regimens and facilitate prevention. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Using imlifidase to elucidate the characteristics and importance of anti-GBM antibodies produced after start of treatment.

Author

Tyrberg, Linnéa, Andersson, Fanny, Uhlin, Fredrik, Hellmark, Thomas, and Segelmark, Mårten

Subjects
ANTINEUTROPHIL cytoplasmic antibodies, IMMUNOGLOBULIN G, IMMUNOGLOBULINS, MONOCLONAL antibodies, BASAL lamina, IGA glomerulonephritis
Abstract

Background Autoantibodies are common in glomerulonephritis, but the clinical benefit of rapid elimination has not been determined, even in anti-glomerular basement membrane (GBM) disease. Even less is known about the importance of autoantibody characteristics, including epitope specificity and immunoglobulin G (IgG) subclass distribution. We aimed to address this by characterizing the autoantibody profile in anti-GBM patients: we utilized samples from the GOOD-IDES-01 (treating GOODpasture's disease with Imunoglobulin G Degrading Enzyme of Streptococcus pyogenous) (ClinicalTrials.gov identifier: NCT03157037) trial , where imlifidase, which cleaves all IgG in vivo within hours, was given to 15 anti-GBM patients. Methods In the GOOD-IDES-01 trial, plasmapheresis was (re)started if anti-GBM antibodies rebounded. Serum samples were collected prospectively for 6 months and analyzed for anti-GBM epitope specificity using recombinant constructs of the EA and EB epitopes, IgG subclass using monoclonal antibodies, and anti-neutrophil cytoplasmic antibodies (ANCA). The results were correlated with clinical data. Results Patients with a rebound (n  = 10) tended to have lower eGFR at 6 months (11 vs 34 mL/min/1.73 m2, P  = .055), and patients with dialysis at 6 months had a higher EB/EA ratio at rebound (0.8 vs 0.5, P  = .047). Moreover, two patients demonstrated increasing epitope restriction and several patients displayed a shift in subclass distribution at rebound. Six patients were double positive for ANCA. ANCA rebound was seen in 50% of patients; only one patient remained ANCA positive at 6 months. Conclusions In this study, rebound of anti-GBM antibodies, especially if directed against the EB epitope, was associated with a worse outcome. This supports the notion that all means should be used to eliminate anti-GBM antibodies. In this study ANCA was removed early and long-term by imlifidase and cyclophosphamide. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

39. EULAR recommendations for the management of ANCA- associated vasculitis: 2022 update.

Author

Hellmich, Bernhard, Alamo, Beatriz Sanchez, Schirmer, Jan H., Berti, Alvise, Blockmans, Daniel, C. Cid, Maria, Holle, Julia U., Hollinger, Nicole, Karadag, Omer, Kronbichler, Andreas, Little, Mark A., Luqmani, Raashid A., Mahr, Alfred, Merkel, Peter A., Mohammad, Aladdin J., Monti, Sara, Mukhtar, Chetan B., Musial, Jacek, Kuehne, Fiona Price, and Segelmark, Mårten

Published
2024
Full Text
View/download PDF

41. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis

Author

Jayne, David R.W., Bruchfeld, Annette N., Harper, Lorraine, Schaier, Matthias, Venning, Michael C., Hamilton, Patrick, Burst, Volker, Grundmann, Franziska, Jadoul, Michel, Szombati, István, Tesař, Vladimír, Segelmark, Mårten, Potarca, Antonia, Schall, Thomas J., Bekker, Pirow, Jayne, David R.W., Bruchfeld, Annette N., Harper, Lorraine, Schaier, Matthias, Venning, Michael C., Hamilton, Patrick, Burst, Volker, Grundmann, Franziska, Jadoul, Michel, Szombati, István, Tesař, Vladimír, Segelmark, Mårten, Potarca, Antonia, Schall, Thomas J., and Bekker, Pirow

Published
2017
Full Text
View/download PDF

45. Results of the first nationwide cohort study of outcomes in dialysis and kidney transplant patients before and after vaccination for COVID-19.

Author

Wijkström, Julia, Caldinelli, Aurora, Bruchfeld, Annette, Nowak, Alexandra, Artborg, Angelica, Stendahl, Maria, Segelmark, Mårten, Lindholm, Bengt, Bellocco, Rino, Rydell, Helena, and Evans, Marie

Subjects
HEMODIALYSIS, KIDNEY transplantation, COVID-19 vaccines, COHORT analysis, RENAL replacement therapy
Abstract

Background Patients on kidney replacement therapy (KRT) have been identified as a vulnerable group during the coronavirus disease 2019 (COVID-19) pandemic. This study reports the outcomes of COVID-19 in KRT patients in Sweden, a country where patients on KRT were prioritized early in the vaccination campaign. Methods Patients on KRT between January 2019 and December 2021 in the Swedish Renal Registry were included. Data were linked to national healthcare registries. The primary outcome was monthly all-cause mortality over 3 years of follow-up. The secondary outcomes were monthly COVID-19-related deaths and hospitalizations. The results were compared with the general population using standardized mortality ratios. The difference in risk for COVID-19-related outcomes between dialysis and kidney transplant recipients (KTRs) was assessed in multivariable logistic regression models before and after vaccinations started. Results On 1 January 2020, there were 4097 patients on dialysis (median age 70 years) and 5905 KTRs (median age 58 years). Between March 2020 and February 2021, mean all-cause mortality rates increased by 10% (from 720 to 804 deaths) and 22% (from 158 to 206 deaths) in dialysis and KTRs, respectively, compared with the same period in 2019. After vaccinations started, all-cause mortality rates during the third wave (April 2021) returned to pre-COVID-19 mortality rates among dialysis patients, while mortality rates remained increased among transplant recipients. Dialysis patients had a higher risk for COVID-19 hospitalizations and death before vaccinations started {adjusted odds ratio [aOR] 2.1 [95% confidence interval (CI) 1.7–2.5]} but a lower risk after vaccination [aOR 0.5 (95% CI 0.4–0.7)] compared with KTRs. Conclusions The COVID-19 pandemic in Sweden resulted in increased mortality and hospitalization rates among KRT patients. After vaccinations started, a distinct reduction in hospitalization and mortality rates was observed among dialysis patients, but not in KTRs. Early and prioritized vaccinations of KRT patients in Sweden probably saved many lives. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

46. Stratified genetic analysis reveals sex differences in MPO-ANCA-associated vasculitis.

Author

Ekman, Diana, Sennblad, Bengt, Knight, Ann, Karlsson, Åsa, Rantapää-Dahlqvist, Solbritt, Berglin, Ewa, Stegmayr, Bernd, Baslund, Bo, Palm, Øyvind, Haukeland, Hilde, Gunnarsson, Iva, Bruchfeld, Annette, Segelmark, Mårten, Ohlsson, Sophie, Mohammad, Aladdin J, Svärd, Anna, Pullerits, Rille, Herlitz, Hans, Söderbergh, Annika, and Omdal, Roald

Subjects
CONFIDENCE intervals, SINGLE nucleotide polymorphisms, ANTINEUTROPHIL cytoplasmic antibodies, ALLELES, SEX distribution, PEROXIDASE, RISK assessment, GENES, GENOTYPES, DESCRIPTIVE statistics, RESEARCH funding, ODDS ratio, VASCULITIS, DISEASE risk factors
Abstract

Objective To identify and genetically characterize subgroups of patients with ANCA-associated vasculitides (AAV) based on sex and ANCA subtype. Methods A previously established SNP dataset derived from DNA sequencing of 1853 genes and genotyping of 1088 Scandinavian cases with AAV and 1589 controls was stratified for sex and ANCA subtype and analysed for association with five top AAV SNPs. rs9274619, a lead variant at the HLA-DQB1/HLA-DQA2 locus previously associated with AAV positive for myeloperoxidase (MPO)-ANCA, was analysed for association with the cumulative disease involvement of ten different organ systems. Results rs9274619 showed a significantly stronger association to MPO-ANCA-positive females than males [ P  = 2.0 × 10−4, OR = 2.3 (95% CI 1.5, 3.5)], whereas proteinase 3 (PR3)-ANCA-associated variants rs1042335, rs9277341 (HLA-DPB1/A1) and rs28929474 (SERPINA1) were equally associated with females and males with PR3-ANCA. In MPO-ANCA-positive cases, carriers of the rs9274619 risk allele were more prone to disease engagement of eyes [ P  = 0.021, OR = 11 (95% CI 2.2, 205)] but less prone to pulmonary involvement [ P  = 0.026, OR = 0.52 (95% CI 0.30, 0.92)]. Moreover, AAV with both MPO-ANCA and PR3-ANCA was associated with the PR3-ANCA lead SNP rs1042335 [ P  = 0.0015, OR = 0.091 (95% CI 0.0022, 0.55)] but not with rs9274619. Conclusions Females and males with MPO-ANCA-positive AAV differ in genetic predisposition to disease, suggesting at least partially distinct disease mechanisms between the sexes. Double ANCA-positive AAV cases are genetically similar to PR3-ANCA-positive cases, providing clues to the clinical follow-up and treatment of these patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results